The trial focuses on adults with Bronchiectasis who have a new infection caused by the bacterium Pseudomonas aeruginosa. The study compares three antibiotic approaches: an inhaled solution containing colistimethate sodium, oral tablets of ciprofloxacin, and a control treatment that looks the same but contains only saline, referred to as placebo.
The purpose of the study is to find out which of these regimens is most effective at clearing the bacteria. Participants are randomly assigned to one of the three groups, receive the assigned medication for a short course, and then are monitored over several months with clinic visits and sample collections.
Effectiveness is judged by microbiological eradication, meaning that laboratory tests no longer detect the bacteria in sputum or other samples after treatment. Additional observations include how often respiratory flare‑ups occur, any side effects, overall well‑being, and any changes in blood tests. The follow‑up continues up to a year to see if the benefit lasts.
Spain 
